Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)

Shyamala C. Navada, MD, Guillermo Garcia-Manero, MD, Ehab L. Atallah, MD, M. Nabeel Rajeh, MD, Jamile M. Shammo, MD, Elizabeth A. Griffiths, MD, Samer K. Khaled, MD, Shaker R. Dakhil, MD, David E. Young, MD, Rosalie Odchimar-Reissig, RN, Afoluso Ronnee Adesanya, MD, Patrick S. Zbyszewski, MBA, Richard C. Woodman, MD, Pierre Fenaux, MD PhD, Lewis R. Silverman, MD

Blood (2019) 134 (Supplement_1): 566.

https://doi.org/10.1182/blood-2019-131676

Published: 2019

Journal Articles

Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the Inspire Study (04-30)

Guillermo Garcia-Manero, MD, Anna Jonasova, MD PhD, Selina M. Luger, MD FRCPC, Aref Al-Kali, MD, David Valcárcel, MD, Erica D. Warlick, MD, Wieslaw W. Jedrzejczak, MD PhD, María Díez-Campelo, MD PhD, Patrick S. Zbyszewski, MBA, Christopher Cavanaugh, Richard C. Woodman, MD, Steven M. Fruchtman, MD, Koichi Takahashi, MD

Blood (2019) 134 (Supplement_1): 3015.

https://doi.org/10.1182/blood-2019-131632

Published: 2019

Journal Articles

The Inspire Study in Higher-Risk Myelodysplastic Syndrome (HR-MDS): A Novel Phase 3 Study Adaptive Design for Hematological Malignancies in Adults

Anna Jonasova, MD PhD, Selina M. Luger, MD FRCPC, Aref Al-Kali, MD, David Valcarcel, Richard C. Woodman, MD, Afoluso Ronnee Adesanya, MD, Nozar Azarnia, PhD, Matthew Parris, Erica D. Warlick, MD, Wieslaw W. Jedrzejczak, MD PhD, María Díez-Campelo, MD PhD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 4249.

https://doi.org/10.1182/blood-2019-132127

Published: 2019

Journal Articles

Efficacy of Treatments in Relapsed or Relapsed and Refractory Multiple Myeloma: An Indirect Treatment Comparison

Paul G. Richardson, Jae Hoon Lee, MD PhD, Istvan Majer, Arun Krishna, Richard C. Woodman, MD

Blood (2014) 124 (21): 2638.

https://doi.org/10.1182/blood.V124.21.2638.2638

Published: 2014

Journal Articles

Efficacy of Nilotinib Vs High-Dose Imatinib Vs Sustaining Standard-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Response to Frontline Imatinib

Soo Young Choi, Sung-Eun Lee, Yun jeong Oh, Soo-Hyun Kim, Richard C. Woodman, Tomasz Szczudlo, MD, Saengsuree Jootar, MD, Hyeoung-Joon Kim, MD PhD, Sang Kyun Sohn, MD PhD, Joon Seong Park, MD, Sung-Hyun Kim, MD PhD, Dae-Young Zang, Suk-Joong Oh, Dong-Wook Kim, MD PhD

Blood (2014) 124 (21): 1816.

https://doi.org/10.1182/blood.V124.21.1816.1816

Published: 2014

Journal Articles

MDR1 Gene Expression Predicts Response and Progression-Free Survival Of Ph+ CML Patients On Second-Line Nilotinib Therapy After Imatinib Failure - 4-Year Follow-Up

Mridul Agrawal, Benjamin Hanfstein, MD, Philipp Erben, MD, Dominik Wolf, MD, Thomas Ernst, Susanne Saussele, MD, Alice Fabarius, PhD, Das Purkayasatha, Richard C. Woodman, MD, Rüdiger Hehlmann, MD, Wolf-Karsten Hofmann, MD, Andreas Hochhaus, MD, Martin C. Müller, MD

Blood (2013) 122 (21): 1494.

https://doi.org/10.1182/blood.V122.21.1494.1494

Published: 2013

Journal Articles

ENESTxtnd: Impact Of Nilotinib Dose Re-Escalation In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP)

Jeff H. Lipton, PhD, MD, Luis Meillon, MD, Vernon Louw, MD, Carolina Pavlovsky, MD, Lee-Yung Shih, MD, Yu Jin, Sandip Acharya, Richard C. Woodman, Timothy P. Hughes, MD, Anna G. Turkina, MD, PhD

Blood (2013) 122 (21): 4009.

https://doi.org/10.1182/blood.V122.21.4009.4009

Published: 2013

Journal Articles

Nilotinib Or High-Dose Imatinib Compared With Standard-Dose Imatinib In Early Chronic Phase CML Patients Who Have Suboptimal Molecular Responses To Standard-Dose Imatinib: Including Updated Data From RE-Nice Study

Soo-Young Choi, Sung-Eun Lee, M.D., Yun Jeong Oh, Soo-Hyun Kim, Richard C. Woodman, Tomasz Szczudlo, Saengsuree Jootar, MD, Hyeoung-Joon Kim, MD, PhD, Sang Kyun Sohn, MD, PhD, Joon Seong Park, MD, Sung-Hyun Kim, MD, PhD, Dae-Young Zang, Suk-Joong Oh, Dong-Wook Kim, MD, PhD

Blood (2013) 122 (21): 1499.

https://doi.org/10.1182/blood.V122.21.1499.1499

Published: 2013

Journal Articles

Assessment of Clinical Safety and Estimate of Survival in Iraqi Patients with Chronic Myeloid Leukemia Switched From Glivec (β-Crystalline Form of Imatinib Mesylate) to an α-Crystalline Copy of Imatinib Mesylate

Marc Botteman, MSc, MA, Matthew Magestro, Alaa Fadhil Alwan, MD, Paul W Manley, PhD, Oleg Zernovak, MD, Richard C. Woodman

Blood (2012) 120 (21): 4439.

https://doi.org/10.1182/blood.V120.21.4439.4439

Published: 2012

Journal Articles

Nilotinib Versus High-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Responses to Standard-Dose Imatinib: Updated Data From RE-Nice Study

Blood (2012) 120 (21): 3775.

https://doi.org/10.1182/blood.V120.21.3775.3775

Published: 2012

Journal Articles

Retrospective Cohort Analysis of Peripheral Arterial Occlusive Disease (PAOD) Events in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Francis J. Giles, MB, MD, FRCPI, FRCPath, Michael J. Mauro, MD, Frank Hong, MD, PhD, MPH, Christine-Elke Ortmann, Richard C. Woodman, Philipp D. LeCoutre, MD, Giuseppe Saglio, MD

Blood (2011) 118 (21): 2757.

https://doi.org/10.1182/blood.V118.21.2757.2757

Published: 2011

Journal Articles

Efficacy of Nilotinib Versus High-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Responses to Standard-Dose Imatinib (RE-NICE Multicenter Study)

Hyun-Gyung Goh, Saengsuree Jootar, Hyeoung-Joon Kim, Sang Kyun Sohn, Joon Seong Park, Sung Hyun Kim, Dae Young Zang, Suk-Joong Oh, Soo-Young Choi, Ju-Hee Bang, Soo-Hyun Kim, Eun-Jung Jang, Sung-Eun Lee, Dongho Kim, Ji-Young Byeun, Richard C. Woodman, Tomasz Szczudlo, Hee Jung Kim, Dong-Wook Kim

Blood (2011) 118 (21): 2765.

https://doi.org/10.1182/blood.V118.21.2765.2765

Published: 2011

Journal Articles

Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib

Jorge E. Cortes, Andreas Hochhaus, Philipp D. le Coutre, Gianantonio Rosti, Javier Pinilla-Ibarz, Elias Jabbour, Kathryn Gillis, Richard C. Woodman, Rick E. Blakesley, Francis J. Giles, Hagop M. Kantarjian, Michele Baccarani

Blood (2011) 117 (21): 5600–5606.

https://doi.org/10.1182/blood-2010-11-318949

Published: 2011

Journal Articles

Molecular Predictors for the Response to Nilotinib Treatment After Acquired Imatinib Failure In Ph+ Chronic Myeloid Leukemia

Mridul Agrawal, Philipp Erben, MD, Benjamin Hanfstein, MD, Armin Leitner, MD, John Reynolds, Richard C. Woodman, MD, Laura Robin, Wolf-Karsten Hofmann, MD, Andreas Hochhaus, MD, Martin C. Müller, MD

Blood (2010) 116 (21): 2283.

https://doi.org/10.1182/blood.V116.21.2283.2283

Published: 2010

Journal Articles

A Review of Mutation Analysis In the TOPS Trial of Standard Dose Versus High Dose IM In CML Suggests That Refinements to the ELN Recommendations for Mutation Screening May Be Appropriate

Susan Branford, PhD, Hyun-Gyung Goh, Barbara Izzo, Lan Beppu, Christine-Elke Ortmann, Kamila Duniec, PhD, Yu Jin, Richard C. Woodman, MD, Fabrizio Pane, MD, Dong-Wook Kim, Jerald P. Radich, MD, Timothy P. Hughes

Blood (2010) 116 (21): 889.

https://doi.org/10.1182/blood.V116.21.889.889

Published: 2010

Journal Articles

Nilotinib Exposure-Response Analysis In Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML)

Francis J. Giles, MB, MD, FRCPI, FRCPath, Ophelia Yin, PhD, FCP, Yen Lin Chia, PhD, Philipp D. le Coutre, MD, Richard C. Woodman, MD, Oliver G. Ottmann, MD, Michele Baccarani, MD, Hagop M. Kantarjian, MD

Blood (2010) 116 (21): 890.

https://doi.org/10.1182/blood.V116.21.890.890

Published: 2010

Journal Articles

Hospitalizations of Patients with Newly Diagnosed CML-CP Treated with Nilotinib or Imatinib: Results From a Randomized Phase III Trial

Jennifer L Beaumont, MS*, John Coombs, PharmD, MBA*, amsi Bollu, V, PhD, MBA*, Richard C. Woodman, MD, David Cella, PhD*

Blood (2010) 116 (21): 3826.

https://doi.org/10.1182/blood.V116.21.3826.3826

Published: 2010

Journal Articles

Proinflammatory state, hepcidin, and anemia in older persons

Luigi Ferrucci, Richard D. Semba, Jack M. Guralnik, William B. Ershler, Stefania Bandinelli, Kushang V. Patel, Kai Sun, Richard C. Woodman, Nancy C. Andrews, Robert J. Cotter, Tomas Ganz, Elizabeta Nemeth, Dan L. Longo

Blood (2010) 115 (18): 3810–3816.

https://doi.org/10.1182/blood-2009-02-201087

Published: 2010

Journal Articles

Response and Outcomes to Nilotinib at 24 Months in Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) and Accelerated Phase (CML-AP) with and without BCR-ABL Mutations.

Jerald P. Radich, MD, Giovanni Martinelli, MD, Andreas Hochhaus, MD, Enrico Gottardi, Simona Soverini, PhD, Susan Branford, PhD, Martin C Müller, MD, Lan Beppu, Yaping Shou, MD, PhD, Ariful Haque, MS, Richard C. Woodman, MD, Hagop M. Kantarjian, MD, Timothy P. Hughes, MD, MBBS, Dong-Wook Kim, MD, PhD, Giuseppe Saglio, MD

Blood (2009) 114 (22): 1130.

https://doi.org/10.1182/blood.V114.22.1130.1130

Published: 2009

Journal Articles

MDR1 Expression and Pre-Treatment Tumor Load Predict Molecular Response in CML Patients On Nilotinib Therapy After Imatinib Failure.

Mridul Agrawal, Philipp Erben, MD, Benjamin Hanfstein, Hannah Daikeler, MD, Juliana Popa, MD, Thomas Schenk, MD, Armin Leitner, MD, Richard C. Woodman, MD, Andreas Hochhaus, MD, Martin C Müller, MD

Blood (2009) 114 (22): 2615.

https://doi.org/10.1182/blood.V114.22.2615.2615

Published: 2009

NARROW

Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)

Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the Inspire Study (04-30)

The Inspire Study in Higher-Risk Myelodysplastic Syndrome (HR-MDS): A Novel Phase 3 Study Adaptive Design for Hematological Malignancies in Adults

Efficacy of Treatments in Relapsed or Relapsed and Refractory Multiple Myeloma: An Indirect Treatment Comparison

Efficacy of Nilotinib Vs High-Dose Imatinib Vs Sustaining Standard-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Response to Frontline Imatinib

MDR1 Gene Expression Predicts Response and Progression-Free Survival Of Ph+ CML Patients On Second-Line Nilotinib Therapy After Imatinib Failure - 4-Year Follow-Up

ENESTxtnd: Impact Of Nilotinib Dose Re-Escalation In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP)

Nilotinib Or High-Dose Imatinib Compared With Standard-Dose Imatinib In Early Chronic Phase CML Patients Who Have Suboptimal Molecular Responses To Standard-Dose Imatinib: Including Updated Data From RE-Nice Study

Assessment of Clinical Safety and Estimate of Survival in Iraqi Patients with Chronic Myeloid Leukemia Switched From Glivec (β-Crystalline Form of Imatinib Mesylate) to an α-Crystalline Copy of Imatinib Mesylate

Nilotinib Versus High-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Responses to Standard-Dose Imatinib: Updated Data From RE-Nice Study

Retrospective Cohort Analysis of Peripheral Arterial Occlusive Disease (PAOD) Events in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Efficacy of Nilotinib Versus High-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Responses to Standard-Dose Imatinib (RE-NICE Multicenter Study)

Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib

Molecular Predictors for the Response to Nilotinib Treatment After Acquired Imatinib Failure In Ph+ Chronic Myeloid Leukemia

A Review of Mutation Analysis In the TOPS Trial of Standard Dose Versus High Dose IM In CML Suggests That Refinements to the ELN Recommendations for Mutation Screening May Be Appropriate

Nilotinib Exposure-Response Analysis In Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML)

Hospitalizations of Patients with Newly Diagnosed CML-CP Treated with Nilotinib or Imatinib: Results From a Randomized Phase III Trial

Proinflammatory state, hepcidin, and anemia in older persons

Response and Outcomes to Nilotinib at 24 Months in Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) and Accelerated Phase (CML-AP) with and without BCR-ABL Mutations.

MDR1 Expression and Pre-Treatment Tumor Load Predict Molecular Response in CML Patients On Nilotinib Therapy After Imatinib Failure.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only